J.P. Morgan Day Three: Biogen Still Shopping For Deals, Sanofi Explains Its View On Oncology

Daily notebook from the J.P. Morgan Healthcare Conference: Biogen is still looking for deals, just smaller; Sanofi's push in immunology has pulled it away from oncology; Sage provides updates on Zurzuvae launch; and Takeda plans a big program for its TYK-2 inhibitor.